Notable insider buying and selling activity across public companies.
Tracking and analysis of reported insider transactions, including executive and director buying or selling. Insider activity can offer insight into internal confidence, valuation perceptions, and potential inflection points.
13,122 total articles
C. Frank Bennett, serving as Executive Vice President and Chief Scientific Officer at Ionis Pharmaceuticals Inc. (NASDAQ:IONS), executed the sale of common stock valued at approximately $1.74 million on July 7, 2026. The transactions, conducted under a Rule 10b5-1 trading plan established in March 2026, involved both directly and indirectly held sh…
Abeona Therapeutics CEO Seshadri Vishwas sold approximately $473,329 worth of company shares on July 9, 2026, to cover tax obligations from restricted stock vesting. The sale occurs as the stock trades near its 52-week high, following a strong first-quarter earnings report that beat analyst expectations on both revenue and earnings per share.
Joseph Walter Vazzano, Chief Financial Officer of Abeona Therapeutics Inc., sold 24,880 shares on July 9, 2026, generating $173,256 to cover tax liabilities from restricted stock vesting. The transaction occurred at prices between $6.86 and $7.04 per share, with a weighted average of $6.9637. This sale reduces his direct holdings to 493,557 shares.…
Brendan M. O’Malley, Senior Vice President and Chief Legal Officer at Abeona Therapeutics Inc. (NASDAQ: ABEO), executed a sale of 12,050 shares of the company's common stock on July 9, 2026. The transaction, valued at $83,912, was conducted to satisfy tax liabilities arising from the vesting of restricted stock awards. This sale occurs as ABEO stoc…
Vasanthavada Madhav, the Chief Commercial Officer at Abeona Therapeutics Inc. (NASDAQ: ABEO), executed a sale of company stock on July 9, 2026. The transaction involved the disposal of 12,606 shares, generating approximately $87,784 in proceeds. Madhav indicated that the sale was necessitated by the need to satisfy tax withholding requirements asso…
Wrap Technologies director John Shulman executed a purchase of 100,000 shares at $1.10 per share on July 8, 2026, totaling $110,000. The acquisition brings his direct holdings to 199,037 shares, with additional indirect interests through Juggernaut Management, LLC. This transaction occurs as Wrap Technologies navigates a period of rapid stock appre…
Scot Cohen, Executive Chairman and CEO of WRAP Technologies, Inc. (NASDAQ:WRAP), has recently executed a series of transactions involving the company's common stock. On July 8, 2026, Cohen purchased 21,740 shares at $1.10 per share, totaling $23,914. This acquisition follows a notable price surge of the stock, which has risen 67% over the past week…
Energy Fuels Inc. (NYSE American: UUUU) President and CEO Ross R. Bhappu has significantly increased his equity stake in the company, purchasing 74,000 shares in a recent transaction. This insider activity occurs against a backdrop of aggressive corporate expansion, including a $1.9 billion acquisition and substantial government financing aimed at …
Ingrid Delaet, Chief Regulatory Officer at Neurocrine Biosciences Inc. (NASDAQ:NBIX), executed a series of stock sales totaling approximately $2.6 million between July 7 and July 9, 2026. The transactions were processed under a Rule 10b5-1 trading plan established in February 2026, ensuring compliance with securities regulations while allowing for …
EverCommerce Inc. (NASDAQ: EVCM) Chief Executive Officer Eric Remer executed multiple sales of company common stock totaling $199,734 on July 7 and July 8, 2026. The transactions, conducted under a Rule 10b5-1 trading plan established in June 2025, reduced his direct holdings while the company navigates a period of mixed financial performance and g…
Sanjit Biswas, Chief Executive Officer of Samsara Inc. (NASDAQ:IOT), executed a series of Class A Common Stock sales totaling approximately $9.67 million across July 7 and July 8, 2026. The transactions, facilitated through various trusts and adhering to Rule 10b5-1 trading plans, reflect ongoing executive liquidity events within the expanding Inte…
John Bicket, Executive Vice President and Chief Technology Officer at Samsara Inc. (NASDAQ:IOT), completed a series of share sales totaling approximately $9.67 million on July 7 and July 8, 2026. The transactions, executed through various trusts and restricted stock units, were conducted at prices ranging from $35.0279 to $38.3473 per share. All sa…
Concentrix Corp (CNXC) President and CEO Christopher A. Caldwell purchased 1,000 shares of the company's common stock on July 8, 2026, totaling $21,249. The transaction follows a second-quarter earnings report that fell short of Wall Street forecasts and a downward revision to the company's full-year growth outlook. Despite the earnings miss, Caldw…
Holly B. Kordasiewicz, Executive Vice President and Chief Development Officer at Ionis Pharmaceuticals Inc (NASDAQ: IONS), sold 362 shares of the company's common stock on July 7, 2026. The transaction, valued at $30,516, was executed at a price of $84.30 per share. This sale was conducted under a Rule 10b5-1 trading plan established by Ms. Kordasi…
Allene M. Diaz, a director at Ionis Pharmaceuticals Inc (NASDAQ: IONS), executed a sale of 10,111 shares of the company's common stock on July 7, 2026, resulting in proceeds totaling $863,637. The transaction was facilitated through a Rule 10b5-1 trading plan adopted in late 2025. This sale follows the acquisition of an equivalent number of shares …
King James Winston, Guidewire Software's Chief Administrative Officer and General Counsel, executed a sale of 1,684 shares on July 9, 2026, under a 10b5-1 trading plan. The transaction, valued at $219,997, occurred as the company navigates a period of mixed financial results, with earnings beating expectations but annual recurring revenue slightly …
Blake Borgeson, a director at Recursion Pharmaceuticals Inc., executed a sale of 40,000 shares of Class A Common Stock on July 7, 2026, totaling $158,500. The transaction was conducted under a Rule 10b5-1 trading plan established on August 31, 2025. Following the sale, Borgeson retains a direct stake of 6,218,287 shares. The sale price ranged betwe…
HRT Financial LP, a significant shareholder in iPower Inc., executed both purchases and sales of the company's common stock in early July 2026, according to a Form 4 filing with the Securities and Exchange Commission. These transactions occurred as iPower advances its strategic initiatives, including a $3 million investment in AI infrastructure and…
Milton C. Ault III, a director and significant shareholder of Universal Safety Products, Inc. (OTC:UUU), has increased his equity stake through recent open market purchases totaling $2,398. The transactions, executed on July 7 and July 8, 2026, occur as the company navigates a period of stock volatility and announces a strategic expansion into digi…
HRT Financial LP, a 10% shareholder in Edible Garden AG Inc. (NASDAQ:EDBL), executed a notable divestment of common stock, according to a filing with the Securities and Exchange Commission. This transaction highlights the ongoing liquidity challenges and valuation pressures facing the vertically integrated cannabis cultivator, which reported a 22.9…
Oregon Community Foundation, a ten percent owner of Jewett Cameron Trading Co Ltd (NASDAQ: JCTC), has executed a recent sale of its holdings in the company. The transaction occurred on July 9, 2026, involving the disposition of 5,282 shares of common stock. This move comes as the company approaches its next earnings report and follows a period of r…
HRT Financial LP, which holds a 10% stake in Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ:SHPH), executed a $100,460 sale of common stock across two days in early July. The disposal occurs as the company finalizes a merger with United Dogecoin Inc., secures renewable energy infrastructure for cryptocurrency mining, and prepares for a 10-for-1 rev…
HRT Financial LP, a ten percent shareholder in Wheeler Real Estate Investment Trust, has executed a net reduction in its position through recent transactions. The activity follows a period of significant stock price decline and coincides with Wheeler's broader corporate actions aimed at stabilizing its capital structure and portfolio.
Immunome Inc. (NASDAQ: IMNM) Chief Business Officer Horn Kinney executed a sale of 1,092 shares on July 7, 2026, valued at $27,300. The transaction was part of a pre-arranged Rule 10b5-1 trading plan established in March 2026. This sale follows the vesting and exercise of employee stock options, resulting in Kinney holding zero direct shares but re…
Robert Hershberg, a director at AtaiBeckley Inc. (NASDAQ:ATAI), executed a series of transactions on July 7, 2026, resulting in the sale of 100,000 shares. The sales were conducted under a Rule 10b5-1 trading plan and followed the exercise of fully vested stock options for the same number of shares. The transaction occurred as the company advances …
